In brief: Narhex, Norwood Abbey, Anadis, Phylogica
Thursday, 02 February, 2006
Narhex Life Sciences (ASX:NLS) has signed a manufacturing contract with Indian, Nasdaq-listed company Dr Reddy's for initial GMP-grade production of the prodrug of Narhex's candidate HIV protease inhibitor, DG35.
Norwood Abbey (ASX:NAL) has begun animal studies for the application of its needle-free injection device for the delivery of a drug to treat arthritis at Massachusetts Institute of Technology (MIT). The MIT studies will also extend to a range of other applications involving delivery of drugs into joints.
Anadis (ASX:ANX) is to chase opportunities in the international market of high-profile sporting organisations, including athletes preparing for competition in the Beijing Olympics in 2008, following the successful analysis that its over-the-counter travellers' diarrhoea product Travelan does not contain any prohibited substances.
Phylogica (ASX:PYC) has secured a European patent for a new high-level drug-screening technique for isolating Phylomer and other drug candidates that block protein interactions involved in disease. Phylogica is developing drugs based on phylomers -- short-chain, bioactive peptides derived from the highly specialised proteins of extremophile microbes.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
